Polytheragene has specific know-how in the synthesis of polymers for biology. Polytheragene develops and commercializes PTG1 and PTG3 for the transfer of nucleic acids and PTG2 for hydrophobic active molecules
The company targets companies involved in the bioproduction of proteins and recombinant viral particles, screening platforms and research laboratories.
Polytheragene invests in gene therapy and mRNA-based therapies.
